---
document_datetime: 2025-12-29 07:05:22
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/pombiliti.html
document_name: pombiliti.html
version: success
processing_time: 0.1073987
conversion_datetime: 2025-12-31 02:44:06.020783
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Pombiliti

[RSS](/en/individual-human-medicine.xml/67649)

##### Authorised

This medicine is authorised for use in the European Union

cipaglucosidase alfa Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Pombiliti](#news-on)
- [More information on Pombiliti](#more-information-on-pombiliti-957)
- [More information on Pombiliti](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Pombiliti is a medicine used to treat adults with late-onset Pompe disease (acid alpha-glucosidase [GAA] deficiency), an inherited disorder in which patients have breathing difficulties and muscle weakness. Pombiliti is used in combination with another medicine, miglustat.

Pombiliti contains the active substance cipaglucosidase alfa.

Expand section

Collapse section

## How is Pombiliti used?

Pombiliti is given by infusion (drip) into a vein every other week. The infusion starts 1 hour after taking miglustat and lasts 4 hours. Pombiliti may be given at home in patients who tolerate their infusions well.

The medicine can only be obtained with a prescription and treatment should be supervised by a physician experienced in the management of patients with Pompe disease or similar diseases.

For more information about using Pombiliti, see the package leaflet or contact your doctor or pharmacist.

## How does Pombiliti work?

Patients with Pompe disease lack an enzyme called acid alpha-glucosidase (GAA) which is important for breaking down glycogen (a complex sugar stored in the body) into glucose (a simple sugar). As a result, glycogen accumulates in the muscles, including the heart and diaphragm (the main breathing muscle under the lungs), causing heart problems, breathing difficulties and muscle weakness.

The active substance in Pombiliti, cipaglucosidase alfa, is an enzyme that acts in the same way as the missing GAA enzyme (i.e. breaking down glycogen into glucose). It replaces GAA and prevents further damage caused by the build-up of glycogen. Pombiliti is given in combination with miglustat, an enzyme stabilizer which helps cipaglucosidase alfa to stay functional.

## What benefits of Pombiliti have been shown in studies?

A main study involving 125 patients showed that Pombiliti in combination with miglustat improved the physical abilities of patients with late-onset Pompe disease. The study looked at changes in the distance patients were able to walk before and after treatment. On average, patients treated with Pombiliti and miglustat for 1 year were able to walk 20 more metres in 6 minutes than they could before treatment.

## What are the risks associated with Pombiliti?

The most common side effects with Pombiliti (which may affect up to 1 in 10 people) are chills, dizziness, flushing, sleepiness, chest discomfort, cough, swelling at the infusion site and pain.

Serious side effects (which may affect up to 1 in 50 people) are itchy rash, serious allergic reactions, fever, feeling faint, difficulty breathing, swelling in the throat, wheezing and low blood pressure.

Pombiliti must not be used in people who have had life-threatening allergic reactions to the active substance or to any of the other ingredients of the medicine. It must also not be used in people who cannot have miglustat.

For the full list of side effects and restrictions, see the package leaflet.

## Why is Pombiliti authorised in the EU?

Pompe disease is a rare and debilitating disease, with patients having life-threatening heart and respiratory problems. Studies show that, when given in combination with miglustat, Pombiliti is effective at improving or stabilising the physical abilities of patients with late-onset Pompe disease. The side effects of Pombiliti, which are mostly mild to moderate, are considered manageable. The European Medicines Agency therefore decided that the benefits of Pombiliti are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Pombiliti?

The company that markets Pombiliti will provide educational materials on home infusion to healthcare professionals who are expected to prescribe, dispense or use Pombiliti. They are intended to provide guidance on how Pombiliti and miglustat should be given to the patients and how to manage risks related to the infusion, such as allergic reactions. Patients will also be provided with a guide on home infusion and an infusion diary to help recognise and report infusion reactions.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pombiliti and miglustat have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Pombiliti in combination with miglustat are continuously monitored. Suspected side effects reported with Pombiliti are carefully evaluated and any necessary action taken to protect patients.

## Other information about Pombiliti

Pombiliti received a marketing authorisation valid throughout the EU on 20 March 2023.

Pombiliti : EPAR - Medicine Overview

Reference Number: EMA/950090/2022

English (EN) (148.11 KB - PDF)

**First published:** 16/05/2023

[View](/en/documents/overview/pombiliti-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-816)

български (BG) (174.92 KB - PDF)

**First published:**

16/05/2023

[View](/bg/documents/overview/pombiliti-epar-medicine-overview_bg.pdf)

español (ES) (147.96 KB - PDF)

**First published:**

16/05/2023

[View](/es/documents/overview/pombiliti-epar-medicine-overview_es.pdf)

čeština (CS) (171.54 KB - PDF)

**First published:**

16/05/2023

[View](/cs/documents/overview/pombiliti-epar-medicine-overview_cs.pdf)

dansk (DA) (147.37 KB - PDF)

**First published:**

16/05/2023

[View](/da/documents/overview/pombiliti-epar-medicine-overview_da.pdf)

Deutsch (DE) (151.59 KB - PDF)

**First published:**

16/05/2023

[View](/de/documents/overview/pombiliti-epar-medicine-overview_de.pdf)

eesti keel (ET) (134.14 KB - PDF)

**First published:**

16/05/2023

[View](/et/documents/overview/pombiliti-epar-medicine-overview_et.pdf)

ελληνικά (EL) (171.07 KB - PDF)

**First published:**

16/05/2023

[View](/el/documents/overview/pombiliti-epar-medicine-overview_el.pdf)

français (FR) (149.62 KB - PDF)

**First published:**

16/05/2023

[View](/fr/documents/overview/pombiliti-epar-medicine-overview_fr.pdf)

hrvatski (HR) (167.46 KB - PDF)

**First published:**

16/05/2023

[View](/hr/documents/overview/pombiliti-epar-medicine-overview_hr.pdf)

italiano (IT) (146.02 KB - PDF)

**First published:**

16/05/2023

[View](/it/documents/overview/pombiliti-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (184.18 KB - PDF)

**First published:**

16/05/2023

[View](/lv/documents/overview/pombiliti-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (169.34 KB - PDF)

**First published:**

16/05/2023

[View](/lt/documents/overview/pombiliti-epar-medicine-overview_lt.pdf)

magyar (HU) (179.89 KB - PDF)

**First published:**

16/05/2023

[View](/hu/documents/overview/pombiliti-epar-medicine-overview_hu.pdf)

Malti (MT) (172.36 KB - PDF)

**First published:**

16/05/2023

[View](/mt/documents/overview/pombiliti-epar-medicine-overview_mt.pdf)

Nederlands (NL) (147.78 KB - PDF)

**First published:**

16/05/2023

[View](/nl/documents/overview/pombiliti-epar-medicine-overview_nl.pdf)

polski (PL) (173.21 KB - PDF)

**First published:**

16/05/2023

[View](/pl/documents/overview/pombiliti-epar-medicine-overview_pl.pdf)

português (PT) (149.02 KB - PDF)

**First published:**

16/05/2023

[View](/pt/documents/overview/pombiliti-epar-medicine-overview_pt.pdf)

română (RO) (175.77 KB - PDF)

**First published:**

16/05/2023

[View](/ro/documents/overview/pombiliti-epar-medicine-overview_ro.pdf)

slovenčina (SK) (170.32 KB - PDF)

**First published:**

16/05/2023

[View](/sk/documents/overview/pombiliti-epar-medicine-overview_sk.pdf)

slovenščina (SL) (168.96 KB - PDF)

**First published:**

16/05/2023

[View](/sl/documents/overview/pombiliti-epar-medicine-overview_sl.pdf)

Suomi (FI) (145.67 KB - PDF)

**First published:**

16/05/2023

[View](/fi/documents/overview/pombiliti-epar-medicine-overview_fi.pdf)

svenska (SV) (146.75 KB - PDF)

**First published:**

16/05/2023

[View](/sv/documents/overview/pombiliti-epar-medicine-overview_sv.pdf)

Pombiliti : EPAR - Risk management plan summary

English (EN) (394.94 KB - PDF)

**First published:** 16/05/2023

[View](/en/documents/rmp-summary/pombiliti-epar-risk-management-plan-summary_en.pdf)

## Product information

Pombiliti : EPAR - Product Information

English (EN) (919.75 KB - PDF)

**First published:** 16/05/2023

**Last updated:** 22/11/2024

[View](/en/documents/product-information/pombiliti-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-628)

български (BG) (1018.19 KB - PDF)

**First published:**

16/05/2023

**Last updated:**

22/11/2024

[View](/bg/documents/product-information/pombiliti-epar-product-information_bg.pdf)

español (ES) (792.36 KB - PDF)

**First published:**

16/05/2023

**Last updated:**

22/11/2024

[View](/es/documents/product-information/pombiliti-epar-product-information_es.pdf)

čeština (CS) (970.56 KB - PDF)

**First published:**

16/05/2023

**Last updated:**

22/11/2024

[View](/cs/documents/product-information/pombiliti-epar-product-information_cs.pdf)

dansk (DA) (1.11 MB - PDF)

**First published:**

16/05/2023

**Last updated:**

22/11/2024

[View](/da/documents/product-information/pombiliti-epar-product-information_da.pdf)

Deutsch (DE) (1.15 MB - PDF)

**First published:**

16/05/2023

**Last updated:**

22/11/2024

[View](/de/documents/product-information/pombiliti-epar-product-information_de.pdf)

eesti keel (ET) (766.59 KB - PDF)

**First published:**

16/05/2023

**Last updated:**

22/11/2024

[View](/et/documents/product-information/pombiliti-epar-product-information_et.pdf)

ελληνικά (EL) (820.32 KB - PDF)

**First published:**

16/05/2023

**Last updated:**

22/11/2024

[View](/el/documents/product-information/pombiliti-epar-product-information_el.pdf)

français (FR) (1.11 MB - PDF)

**First published:**

16/05/2023

**Last updated:**

22/11/2024

[View](/fr/documents/product-information/pombiliti-epar-product-information_fr.pdf)

hrvatski (HR) (774.72 KB - PDF)

**First published:**

16/05/2023

**Last updated:**

22/11/2024

[View](/hr/documents/product-information/pombiliti-epar-product-information_hr.pdf)

íslenska (IS) (780.76 KB - PDF)

**First published:**

16/05/2023

**Last updated:**

22/11/2024

[View](/is/documents/product-information/pombiliti-epar-product-information_is.pdf)

italiano (IT) (1.12 MB - PDF)

**First published:**

16/05/2023

**Last updated:**

22/11/2024

[View](/it/documents/product-information/pombiliti-epar-product-information_it.pdf)

latviešu valoda (LV) (782.8 KB - PDF)

**First published:**

16/05/2023

**Last updated:**

22/11/2024

[View](/lv/documents/product-information/pombiliti-epar-product-information_lv.pdf)

lietuvių kalba (LT) (903.56 KB - PDF)

**First published:**

16/05/2023

**Last updated:**

22/11/2024

[View](/lt/documents/product-information/pombiliti-epar-product-information_lt.pdf)

magyar (HU) (923.85 KB - PDF)

**First published:**

16/05/2023

**Last updated:**

22/11/2024

[View](/hu/documents/product-information/pombiliti-epar-product-information_hu.pdf)

Malti (MT) (774.31 KB - PDF)

**First published:**

16/05/2023

**Last updated:**

22/11/2024

[View](/mt/documents/product-information/pombiliti-epar-product-information_mt.pdf)

Nederlands (NL) (933.87 KB - PDF)

**First published:**

16/05/2023

**Last updated:**

22/11/2024

[View](/nl/documents/product-information/pombiliti-epar-product-information_nl.pdf)

norsk (NO) (959.17 KB - PDF)

**First published:**

16/05/2023

**Last updated:**

22/11/2024

[View](/no/documents/product-information/pombiliti-epar-product-information_no.pdf)

polski (PL) (675.23 KB - PDF)

**First published:**

16/05/2023

**Last updated:**

22/11/2024

[View](/pl/documents/product-information/pombiliti-epar-product-information_pl.pdf)

português (PT) (959.24 KB - PDF)

**First published:**

16/05/2023

**Last updated:**

22/11/2024

[View](/pt/documents/product-information/pombiliti-epar-product-information_pt.pdf)

română (RO) (787.16 KB - PDF)

**First published:**

16/05/2023

**Last updated:**

22/11/2024

[View](/ro/documents/product-information/pombiliti-epar-product-information_ro.pdf)

slovenčina (SK) (779.93 KB - PDF)

**First published:**

16/05/2023

**Last updated:**

22/11/2024

[View](/sk/documents/product-information/pombiliti-epar-product-information_sk.pdf)

slovenščina (SL) (782.92 KB - PDF)

**First published:**

16/05/2023

**Last updated:**

22/11/2024

[View](/sl/documents/product-information/pombiliti-epar-product-information_sl.pdf)

Suomi (FI) (1.53 MB - PDF)

**First published:**

16/05/2023

**Last updated:**

22/11/2024

[View](/fi/documents/product-information/pombiliti-epar-product-information_fi.pdf)

svenska (SV) (1.05 MB - PDF)

**First published:**

16/05/2023

**Last updated:**

22/11/2024

[View](/sv/documents/product-information/pombiliti-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0012 12/09/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Pombiliti : EPAR - All authorised presentations

English (EN) (55.71 KB - PDF)

**First published:** 16/05/2023

[View](/en/documents/all-authorised-presentations/pombiliti-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-646)

български (BG) (65.72 KB - PDF)

**First published:**

16/05/2023

[View](/bg/documents/all-authorised-presentations/pombiliti-epar-all-authorised-presentations_bg.pdf)

español (ES) (60.31 KB - PDF)

**First published:**

16/05/2023

[View](/es/documents/all-authorised-presentations/pombiliti-epar-all-authorised-presentations_es.pdf)

čeština (CS) (69.14 KB - PDF)

**First published:**

16/05/2023

[View](/cs/documents/all-authorised-presentations/pombiliti-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (50.9 KB - PDF)

**First published:**

16/05/2023

[View](/da/documents/all-authorised-presentations/pombiliti-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (56.93 KB - PDF)

**First published:**

16/05/2023

[View](/de/documents/all-authorised-presentations/pombiliti-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (48.25 KB - PDF)

**First published:**

16/05/2023

[View](/et/documents/all-authorised-presentations/pombiliti-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (70.29 KB - PDF)

**First published:**

16/05/2023

[View](/el/documents/all-authorised-presentations/pombiliti-epar-all-authorised-presentations_el.pdf)

français (FR) (53.29 KB - PDF)

**First published:**

16/05/2023

[View](/fr/documents/all-authorised-presentations/pombiliti-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (126.11 KB - PDF)

**First published:**

16/05/2023

[View](/hr/documents/all-authorised-presentations/pombiliti-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (53.87 KB - PDF)

**First published:**

16/05/2023

[View](/is/documents/all-authorised-presentations/pombiliti-epar-all-authorised-presentations_is.pdf)

italiano (IT) (52.77 KB - PDF)

**First published:**

16/05/2023

[View](/it/documents/all-authorised-presentations/pombiliti-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (56.63 KB - PDF)

**First published:**

16/05/2023

[View](/lv/documents/all-authorised-presentations/pombiliti-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (68.37 KB - PDF)

**First published:**

16/05/2023

[View](/lt/documents/all-authorised-presentations/pombiliti-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (57.38 KB - PDF)

**First published:**

16/05/2023

[View](/hu/documents/all-authorised-presentations/pombiliti-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (70.45 KB - PDF)

**First published:**

16/05/2023

[View](/mt/documents/all-authorised-presentations/pombiliti-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (55.17 KB - PDF)

**First published:**

16/05/2023

[View](/nl/documents/all-authorised-presentations/pombiliti-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (53.37 KB - PDF)

**First published:**

16/05/2023

[View](/no/documents/all-authorised-presentations/pombiliti-epar-all-authorised-presentations_no.pdf)

polski (PL) (72.53 KB - PDF)

**First published:**

16/05/2023

[View](/pl/documents/all-authorised-presentations/pombiliti-epar-all-authorised-presentations_pl.pdf)

português (PT) (64.54 KB - PDF)

**First published:**

16/05/2023

[View](/pt/documents/all-authorised-presentations/pombiliti-epar-all-authorised-presentations_pt.pdf)

română (RO) (57.36 KB - PDF)

**First published:**

16/05/2023

[View](/ro/documents/all-authorised-presentations/pombiliti-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (65.58 KB - PDF)

**First published:**

16/05/2023

[View](/sk/documents/all-authorised-presentations/pombiliti-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (57.89 KB - PDF)

**First published:**

16/05/2023

[View](/sl/documents/all-authorised-presentations/pombiliti-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (52.71 KB - PDF)

**First published:**

16/05/2023

[View](/fi/documents/all-authorised-presentations/pombiliti-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (49.74 KB - PDF)

**First published:**

16/05/2023

[View](/sv/documents/all-authorised-presentations/pombiliti-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Pombiliti Active substance Cipaglucosidase alfa International non-proprietary name (INN) or common name cipaglucosidase alfa Therapeutic area (MeSH) Glycogen Storage Disease Type II Anatomical therapeutic chemical (ATC) code A16AB

### Pharmacotherapeutic group

Other alimentary tract and metabolism products

### Therapeutic indication

Pombiliti (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset Pompe disease (acid ?-glucosidase [GAA] deficiency).

## Authorisation details

EMA product number EMEA/H/C/005703

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Amicus Therapeutics Europe Limited

Block 1, Blanchardstown Corporate Park Ballycoolin Road Blanchardstown Dublin 15 D15 AKK1 Ireland

Opinion adopted 15/12/2022 Marketing authorisation issued 20/03/2023 Revision 1

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Pombiliti : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (160.48 KB - PDF)

**First published:** 22/11/2024

[View](/en/documents/procedural-steps-after/pombiliti-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Pombiliti : Orphan Maintenance Assessment Report (initial authorisation)

Adopted

Reference Number: EMA/OD/0000098435

English (EN) (1.07 MB - PDF)

**First published:** 30/05/2023

[View](/en/documents/orphan-maintenance-report/pombiliti-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Pombiliti : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/CHMP/794395/2022

English (EN) (1.44 MB - PDF)

**First published:** 16/05/2023

**Last updated:** 24/01/2025

[View](/en/documents/assessment-report/pombiliti-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Pombiliti

Adopted

Reference Number: EMA/CHMP/794393/2022

English (EN) (134.79 KB - PDF)

**First published:** 16/12/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-pombiliti_en.pdf)

#### News on Pombiliti

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-december-2022) 16/12/2022

#### More information on Pombiliti

This product is no longer an orphan medicine. It was originally designated an orphan medicine ( [https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2000](/en/medicines/human/orphan-designations/eu-3-18-2000) ) on 21 March 2018.

Please note that this product (marketed as [Pombiliti](/en/medicines/human/EPAR/pombiliti) ) was withdrawn from the Community register of orphan medicinal products by the European Commission in March 2023 at the time of the granting of a marketing authorisation.

#### More information on Pombiliti

- [A GLOBAL PROSPECTIVE OBSERVATIONAL REGISTRY OF PATIENTS WITH POMPE DISEASE - post-authorisation study](https://catalogues.ema.europa.eu/study/107300)

**This page was last updated on** 22/11/2024

## Share this page

[Back to top](#main-content)